Biosynex has acquired Para’kito
Biosynex has acquired Para’kito, operated by Hong-Kong based Evergreen Land Ltd. The transaction includes assets and IP and the exclusive right to commercialize the brand in Europe, Africa and South America.
Created in 2005, Biosynex is a leading public health player in France and Europe. The group develops, manufactures and markets medical devices for screening, diagnosis and prevention. Biosynex is the French market leader in the design and distribution of rapid tests (RDT), commercialized in 90+ countries. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, resellers and department stores. In 2021, the group generated over US$400 million of sales.
Launched in 2008, Para’kito is the leading European brand in the prevention and care of mosquito bites. The company provides a complete range of anti-mosquito bracelets and sprays based on 100% natural formulas, with a proprietary technology, and distributed via two channels: pharmacies and e-commerce. Para’kito is present in more than 30 countries and supplies 5,000+ pharmacies in France. In 2021, the brand generated over US$7 million of sales in Europe.
Oaklins’ team in France acted as M&A advisor to Biosynex in this transaction.
Talk to the deal team
Related deals
Afric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn moreBayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn more